Sensei Biotherapeutics, Inc. (SNSE) Stock Price & Analysis
Sensei Biotherapeutics, Inc. (SNSE) fell 2.85% to USD 12.63 as of June 10, 2026 at 02:16 UTC, according to Nexqual real-time market data.
SNSE last closed at USD 13; the session ranged USD 12.35–13.18 on volume of 54,597 shares. Market capitalization is $16.95M, with a 52-week range of USD 5.6–36.76 (NCM). Source: Nexqual, June 10, 2026 at 02:16 UTC.
Key Statistics (as of June 10, 2026 at 02:16 UTC)
| Price | USD 12.63 |
|---|---|
| Change | ▼ 2.85% (down) |
| Previous Close | USD 13 |
| Open | USD 12.81 |
| Day Range | USD 12.35 – 13.18 |
| 52-Week Range | USD 5.6 – 36.76 |
| Volume | 54,597 shares |
| Market Cap | $16.95M |
| Exchange | NCM |
Technical Analysis (SNSE)
Nexqual's technical model rates SNSE "SELL" based on 3 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:16 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.94 (oversold) |
| vs SMA50 | Below (USD 24.5) |
| MACD | -2.86 (negative) |
Analyst Ratings (SNSE)
Wall Street analysts rate SNSE "Strong Buy" based on 3 analysts, with a mean price target of USD 51.67 (range USD 50–55), per Nexqual as of June 10, 2026 at 02:16 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 51.67 |
| High Target | USD 55 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SNSE)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -131.45 vs est -0.62 ▼ miss |
| 2025-12-31 | USD -3.74 vs est -4.81 ▲ beat |
| 2025-09-30 | USD -3.62 vs est -4.11 ▲ beat |
| 2025-06-30 | USD -3.91 vs est -5 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financials & Fundamentals (SNSE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 14.39 |
| Total Cash | $202.79M |
| Total Debt | $1.04M |
| Free Cash Flow | $-92.24M |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financial Health Score (SNSE)
Nexqual rates Sensei Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $203M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$24M |
| Efficiency | Mixed — No data |
Ownership (SNSE)
| Insider Ownership | +28.29% |
|---|---|
| Institutional Ownership | +153.02% |
| Shares Outstanding | 1.34M |
| Float | 811,874 |
| Short % of Float | +84.60% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Leadership (SNSE)
Sensei Biotherapeutics, Inc. is led by Christopher W. Gerry (age 45), President, General Counsel, Secretary & Director, per Nexqual as of June 10, 2026 at 02:16 UTC.
| President, General Counsel, Secretary & Director | Christopher W. Gerry (age 45) |
|---|---|
| COO & Director | Anand Parikh Esq. (age 39) |
| Vice President of Investor Relations & Communications | Lora Pike |
Major Backers & Investors (SNSE)
Notable institutional backers of Sensei Biotherapeutics, Inc. include Cormorant Asset Management, LP, Millennium Management, Franklin Resources, Inc., according to Nexqual as of June 10, 2026 at 02:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Cormorant Asset Management, LP | 22.82% |
| Millennium Management | 10.92% |
| Franklin Resources, Inc. | 9.95% |
| Stempoint Capital LP | 9.9% |
| Caligan Partners, LP | 9.39% |
| Trails Edge Capital Partners, LP | 9.31% |
| Marshall Wace LLP | 4.9% |
| Goldman Sachs | 4.59% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
From Sensei Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
- The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
- It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
- The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRZN | Surrozen, Inc. | USD 21.5 | ▼ 0.09% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.37 | ▼ 4.46% |
| TIL | Instil Bio, Inc. | USD 8.02 | ▼ 0.62% |
| INAB | IN8bio, Inc. | USD 1.45 | ▲ 0% |
| VOR | Vor Biopharma Inc. | USD 13.28 | ▲ 0.91% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:16 UTC. This page is informational and not investment advice.